PUBLICACIONES

El objetivo de este informe es estimar indicadores que permitan medir el desempeño de los centros que realizan procedimientos de Intervenciones Coronarias Percutáneas (ICP) bajo la cobertura financiera del FNR. Presentado en el Congreso de HATi en Rio de Janeiro en 2011.

El Fondo Nacional de Recursos (FNR) inició en el año 2005 un proceso de incorporación de medicamentos de alto costo a su canasta de cobertura financiera. Dentro de los medicamentos incorporados se incluyó el tratamiento de algunas patologías oncológicas en determinadas condiciones, las cuales fueron establecidas en las respectivas normativas de cobertura. En este informe se realizó un estudio observacional de la cohorte de pacientes que iniciaron tratamiento bajo cobertura del FNR desde el inicio de la cobertura en octubre de 2006 hasta el 31 de marzo de 2009.

High cost medicines and treatments are funded, in Uruguay, by one institution which manages a national insurance mandatory to all citizens. It provides universal coverage based on protocols built according to based-evidence medicine and to equality and sustainability criteria. Tacrolimus is financed for immunosuppressive treatment in solid organs transplantation. The original trademark was exclusively provided until May 2009, when a generic was introduced with a significant cost reduction.

Introduction: The NRF is the organization nancing in Uruguay the treatment of the three renal replacement techniques (RRT): kidney transplantation (TxR), peritoneal dialysis (PD) and hemodialysis (HD). No previous studies have been performed in Uruguay. Objective: Assess and compare the magnitude of expenses and cost-efectiveness among the RRTs. Table 1. MEAN COST-EFFECTIVENESS RATIO ANALYSIS Methods: Retrospective cohort study of the three techniques in year 2005 incident patients. The “end point” studied was death for dialysis and graft survival for TxR. All healthcare costs were estimated in US dollars per patient, per year and per technique by information provided by the NRF. A Kaplan Meier Survival Analysis and mean cost-eectiveness ratio analysis were made. Subpopulations waiting for TxR in this period were compared to transplantation patients.